Biogen (BIIB) Tops Q3 EPS by 66c, Updates FY Guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $194.25 -7.07%
EPS Growth %: -42.0%
Financial Fact:
Amortization of acquired intangible assets: 99.7M
Today's EPS Names:
CCEL, FNGR, FAST, More
EPS Growth %: -42.0%
Financial Fact:
Amortization of acquired intangible assets: 99.7M
Today's EPS Names:
CCEL, FNGR, FAST, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q3 EPS of $4.77, $0.66 better than the analyst estimate of $4.11. Revenue for the quarter came in at $2.78 million versus the consensus estimate of $2.67 million.
GUIDANCE:
Biogen sees FY2021 EPS of $18.85-$19.35, versus the consensus of $18.61. Biogen sees FY2021 revenue of $10.8-10.9 billion, versus the consensus of $10.76 billion.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citigroup (C) Tops Q2 EPS by 42c
- Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
- FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
